Monitoring for which results is essential when treating a client with ganciclovir?

Monitoring complete blood cell count (CBC) is essential when treating a client with ganciclovir because ganciclovir has the potential to cause myelosuppression, which can lead to neutropenia, anemia, and thrombocytopenia. These conditions can significantly impact a patient’s immune response and ability to clot, making it crucial to regularly assess blood cell levels throughout the treatment. Keeping track of the CBC ensures that any decreases in white blood cells, red blood cells, or platelets can be identified early and managed appropriately, thereby reducing the risk of serious infections or bleeding complications during the course of therapy.

While monitoring blood glucose levels, liver function tests, and electrolyte panels can be important in specific contexts, they are not the primary focus when it comes to the effects of ganciclovir. Blood glucose levels might be monitored in patients with diabetes or metabolic concerns, liver function tests could be relevant for other medications, and electrolyte panels may be necessary due to other health conditions or medications. However, these parameters do not specifically relate to the direct hematological effects of ganciclovir treatment.